Director buys 245K Lucid Diagnostics (NASDAQ: LUCD) shares in market

Rhea-AI Filing Summary

Lucid Diagnostics Inc. director Dennis Matheis reported an open-market purchase of 245,000 shares of common stock. The weighted average purchase price was $1.0011 per share, with individual trade prices ranging from $0.9375 to $1.0200. Following these purchases, he directly owns 1,033,443 shares.

Insider Trade Summary

Net Buyer: 245,000 shares ($245,270)

Net Buy 1 txn

Insider Matheis Dennis

Role null

Bought 245,000 shs ($245K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	245,000	$1.0011	$245K

Holdings After Transaction: Common Stock — 1,033,443 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 245,000 shares Weighted average price: $1.0011 per share Post-transaction holdings: 1,033,443 shares +1 more

4 metrics

Shares purchased 245,000 shares Open-market common stock purchase

Weighted average price $1.0011 per share Average price for 245,000-share purchase

Post-transaction holdings 1,033,443 shares Direct ownership after the purchase

Trade price range $0.9375–$1.0200 per share Range of individual transaction prices

Key Terms

open-market purchase, weighted average purchase price, non-derivative, Form 4

4 terms

open-market purchase financial

"The transaction is classified as an open-market purchase of common stock."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The price reported in Column 4 is a weighted average purchase price."

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

non-derivative financial

"The filing shows this as a non-derivative common stock transaction."

Form 4 regulatory

"What does the Form 4 footnote reveal about the Lucid Diagnostics (LUCD) insider trade prices?"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matheis Dennis

(Last) (First) (Middle)

360 MADISON AVENUE, 25TH FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		P		245,000	A	$1.0011(1)	1,033,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.9375 to $1.0200, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

	/s/ Michael A. Gordon, by power of attorney	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Lucid Diagnostics (LUCD) director Dennis Matheis report?

Director Dennis Matheis reported buying 245,000 Lucid Diagnostics shares in an open-market purchase. The filing shows this as a non-derivative common stock transaction, indicating he increased his direct equity stake in the company through market purchases.

At what price did Dennis Matheis buy Lucid Diagnostics (LUCD) shares?

The weighted average price was $1.0011 per share for the 245,000 Lucid Diagnostics shares. A footnote explains the trades occurred in multiple transactions, with prices ranging from $0.9375 to $1.0200 per share, inclusive, across the reported purchases.

How many Lucid Diagnostics (LUCD) shares does Dennis Matheis hold after the reported purchase?

After the reported open-market purchase, Dennis Matheis directly owns 1,033,443 Lucid Diagnostics common shares. This total reflects his holdings following the 245,000-share acquisition disclosed, giving investors a clearer view of his current direct ownership position.

What does the Form 4 footnote reveal about the Lucid Diagnostics (LUCD) insider trade prices?

The footnote states the reported price is a weighted average for the 245,000 shares. It notes the shares were bought in multiple transactions, with individual trade prices between $0.9375 and $1.0200, and offers to provide detailed trade-by-trade pricing upon request.

Was the Lucid Diagnostics (LUCD) insider transaction an open-market purchase or another type of trade?

The transaction is classified as an open-market purchase of common stock. The Form 4 lists transaction code “P” and describes it as a purchase in an open market or private transaction, confirming it was a straightforward buy rather than an option exercise or gift.